Implantable magnetic relaxation sensors measure cumulative exposure to cardiac biomarkers

Abstract

Molecular biomarkers can be used as objective indicators of pathologic processes. Although their levels often change over time, their measurement is often constrained to a single time point. Cumulative biomarker exposure would provide a fundamentally different kind of measurement to what is available in the clinic. Magnetic resonance relaxometry can be used to noninvasively monitor changes in the relaxation properties of antibody-coated magnetic particles when they aggregate upon exposure to a biomarker of interest. We used implantable devices containing such sensors to continuously profile changes in three clinically relevant cardiac biomarkers at physiological levels for up to 72 h. Sensor response differed between experimental and control groups in a mouse model of myocardial infarction and correlated with infarct size. Our prototype for a biomarker monitoring device also detected doxorubicin-induced cardiotoxicity and can be adapted to detect other molecular biomarkers with a sensitivity as low as the pg/ml range.

A Smart Mobile Lab-on-Chip-Based Medical Diagnostics System Architecture Designed for Evolvability

“…Despite the challenges associated with a highly complex socio-technical system context and the current lack of clear LoC-based PoC IVMT system design methodologies, we believe that such a design for evolvability can promote end-user system adoption. We also conjecture that most of the observations and some of the architectural features evoked in this work may not only apply to LoCbased PoC IVMT systems but also to the emerging Lab-ina-Body systems and applications [44]- [46].…”

Improving Prediction of Cardiovascular Complications of Cancer Therapy: What Does the Future hold?

“…Developments in other imaging techniques such as cardiac magnetic resonance also offer intriguing promise in imaging myocardial fibrosis and cell injury in vivo [28][29][30][31][32] but have yet to be validated in prospective clinical cohorts of patients with cardiotoxicity.…”

Cardiovascular therapy through nanotechnology – how far are we still from bedside?

“…In a study by Ling et al (52), magnetic resonance relaxometry was used to noninvasively monitor changes in the relaxation properties of antibody-coated magnetic particles when they aggregate upon exposure to a biomarker of interest. As the single-point measurements often do not reflect the directions of the underlying pathologic process, thus hindering diagnostic and prognostic decisions, the authors of this innovative method applied implantable devices containing sensors of three clinically relevant cardiac biomarkers: cTnI, creatinine kinase and myoglobin, to continuously monitor biomarker levels for up to 72 h, with a detection level as low as the pg/mL range.…”